Select Page

DiaCarta technologies deliver faster, more sensitive results for diagnostic and molecular genetic testing.

Service overview

CLIA Lab Services

DiaCarta’s state-of-the-art GMP-compliant lab space is over 18,000 square feet. With CA CLIA certification, DiaCarta is dedicated to providing the highest quality facilities that are capable of manufacturing the most advanced molecular diagnostic tools.
Learn More

OptiSeq™ NGS Targeted Sequencing Service Platform

No more costly and time-consuming deep sequencing! DiaCarta’s OptiSeq™ Next-Gen sequencing platform removes the cost and time barriers by reducing the sequencing depth by a factor of up to 100X and enabling ultra-sensitive detection of genetic mutations. The platform combines with the proprietary XNA technology that only hybridizes the wild-type template. That way, only the mutant template is amplified and sequenced. 500 sequencing reads on the OptiSeq™ platform are equivalent to 50,000 reads without using the platform.
Learn More

Next-Gen Sequencing Service

DiaCarta’s Next-Gen Sequencing service is an end to end solution for your tissue and liquid biopsy samples. With a streamlined workflow and dedicated in-house team, we offer quick turnaround time from sample to result.
Learn More

Companion Diagnostics

DiaCarta offers a range of customizable testing services. From single-gene QClamp® qPCR tests to QClamp-NGS panels, DiaCarta is committed to providing companion diagnostic development services customized to fit your needs. Additionally, DiaCarta offers unique project management services to ensure your project is completed in a timely manner and ready for regulatory submission. We provide customized molecular tests on FFPE samples, liquid biopsy samples, and challenging small biopsies and cytology samples (fine needle aspirates, effusions, and CSF).
Learn More

Personalized CAR-T Immunotherapy Platform

In the era of the Cancer MoonShot 2020 Program – the nation’s most comprehensive cancer collaborative initiative to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients, DiaCarta and ProMab have joined hands to offer the next-generation Chimeric Antigen Receptor T-Cell (CAR-T) immunotherapy platform.
Learn More

Register and Learn!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!